14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SKIN vs HELE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
HELE Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)
HELE Overall Winner
6-Pillar Tally: SKIN 1 – 5 HELE
Matrix Metrics: SKIN 1 – 9 HELE
As of Nov 16, 2026, Helen Of Troy Ltd (HELE) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas HELE carries 31.0/100 (SELL) at $37.65 (11.5x Forward P/E, 5.5% operating margin).
Composite vs. Pillar Nuance: While SKIN currently prints a higher short-term Unified Composite Score (34.1/100 SELL vs. HELE 31.0/100 SELL), HELE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.5% vs. 2.4% operating margin) and revenue trajectory (+2.1% vs. -2.1% YoY).
Defensive Composite Rating Caution: Although HELE compares more favorably head-to-head, both SKIN (34.1/100 SELL) and HELE (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment64.8% of Rev ($187M)
90D Engineering Disclosures0 Published
HELE Moat ProfileCyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $872.9M market capitalization and 5.5% operating margin.
OpEx & R&D Reinvestment40.3% of Rev ($736M)
90D Engineering Disclosures0 Published
Investor FAQ SKIN vs HELE Key Questions & Quantitative Answers
As of Nov 16, 2026, Helen Of Troy Ltd (HELE) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas HELE carries 31.0/100 (SELL) at $37.65 (11.5x Forward P/E, 5.5% operating margin). Composite vs. Pillar Nuance: While SKIN currently prints a higher short-term Unified Composite Score (34.1/100 SELL vs. HELE 31.0/100 SELL), HELE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.5% vs. 2.4% operating margin) and revenue trajectory (+2.1% vs. -2.1% YoY). Defensive Composite Rating Caution: Although HELE compares more favorably head-to-head, both SKIN (34.1/100 SELL) and HELE (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
HELE leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with HELE at +2.1% YoY revenue growth and +24.9% YoY earnings growth on $1.83B TTM revenue (45.8% gross margin, 5.5% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SKIN cumulative revenue shifted +76.5% while HELE shifted +14.7%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 40.3% of Rev ($736M) (0 disclosures) for HELE.
HELE screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas HELE trades at 11.5x Forward P/E, 9.2x Trailing P/E, 0.97x PEG, and 0.9x EV/Revenue (8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus HELE (-11.2% ROE) capital efficiency.
In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, HELE carries 33.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.81β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.